Literature DB >> 16061044

Treatment of multiple-risk patients: using combination therapy to treat beyond LDL lowering.

Howard S Weintraub1.   

Abstract

During the past 25 years, the role of traditional "risk factors" in the genesis of atherosclerotic vascular disease has been convincingly validated. The impact of elevated low-density lipoprotein cholesterol, hypertension, type II diabetes, and metabolic syndrome are now well accepted. However, until recently, there was guilt by association without a clear understanding of the manner in which the crime was committed. It is now acknowledged that the presence of multiple risk factors can increase the likelihood of an ischemic event. This has become a great concern, given the very high prevalence of patients who fall into this category. In light of this information, the mandate for appropriate guideline-driven therapy has become even stronger, and we must consider the use of multiple medications to effectively neutralize this risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16061044     DOI: 10.1007/s11906-005-0023-2

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  31 in total

Review 1.  Endothelium-dependent effects of statins.

Authors:  Sebastian Wolfrum; Kristin S Jensen; James K Liao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-02-27       Impact factor: 8.311

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men.

Authors:  G Nickenig; A T Bäumer; Y Temur; D Kebben; F Jockenhövel; M Böhm
Journal:  Circulation       Date:  1999-11-23       Impact factor: 29.690

4.  Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes.

Authors:  Kwang Kon Koh; Michael J Quon; Seung Hwan Han; Jeong Yeal Ahn; Dong Kyu Jin; Hyung Sik Kim; Dae Sung Kim; Eak Kyun Shin
Journal:  Hypertension       Date:  2005-05-09       Impact factor: 10.190

5.  ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.

Authors:  Allen J Taylor; Steven M Kent; Patrick J Flaherty; Louis C Coyle; Thor T Markwood; Marina N Vernalis
Journal:  Circulation       Date:  2002-10-15       Impact factor: 29.690

6.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

7.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.

Authors:  C J Packard; D S O'Reilly; M J Caslake; A D McMahon; I Ford; J Cooney; C H Macphee; K E Suckling; M Krishna; F E Wilkinson; A Rumley; G D Lowe
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

8.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

9.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Authors:  Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

Review 10.  Interactions between hypercholesterolemia and hypertension: implications for therapy.

Authors:  Claudio Borghi
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-09       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.